Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia | 14 | 2024 | 796 | 5.580 |
Why?
|
| Bronchiolitis Obliterans | 9 | 2024 | 94 | 5.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2024 | 7044 | 2.400 |
Why?
|
| Lung | 19 | 2024 | 3298 | 2.120 |
Why?
|
| Lung Transplantation | 3 | 2023 | 383 | 1.790 |
Why?
|
| Asthma | 12 | 2023 | 895 | 1.760 |
Why?
|
| Insurance | 2 | 2022 | 13 | 1.590 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2024 | 5574 | 1.480 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2023 | 216 | 1.480 |
Why?
|
| Lung Neoplasms | 14 | 2024 | 12033 | 1.430 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 444 | 1.280 |
Why?
|
| Graft vs Host Disease | 5 | 2023 | 2810 | 1.280 |
Why?
|
| Respiratory Tract Infections | 5 | 2024 | 408 | 1.200 |
Why?
|
| Immunocompromised Host | 6 | 2025 | 719 | 1.200 |
Why?
|
| Respiratory Function Tests | 6 | 2024 | 354 | 1.150 |
Why?
|
| Neoplasms | 14 | 2024 | 15927 | 0.980 |
Why?
|
| Immunotherapy | 11 | 2024 | 3557 | 0.980 |
Why?
|
| Forced Expiratory Volume | 4 | 2024 | 327 | 0.950 |
Why?
|
| Bronchi | 3 | 2017 | 325 | 0.940 |
Why?
|
| Airway Remodeling | 5 | 2021 | 28 | 0.900 |
Why?
|
| Transplant Recipients | 3 | 2020 | 337 | 0.890 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2024 | 62 | 0.890 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1956 | 0.770 |
Why?
|
| Vital Capacity | 2 | 2021 | 140 | 0.760 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 4372 | 0.750 |
Why?
|
| Radiation Pneumonitis | 1 | 2023 | 313 | 0.750 |
Why?
|
| Catheter Ablation | 3 | 2014 | 575 | 0.730 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2024 | 625 | 0.710 |
Why?
|
| Humans | 78 | 2025 | 270740 | 0.680 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2024 | 7783 | 0.670 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2023 | 7265 | 0.640 |
Why?
|
| Retrospective Studies | 24 | 2024 | 39890 | 0.640 |
Why?
|
| Rubulavirus | 1 | 2018 | 8 | 0.620 |
Why?
|
| Tracheostomy | 1 | 2021 | 255 | 0.610 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2023 | 1060 | 0.590 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 344 | 0.580 |
Why?
|
| Multidetector Computed Tomography | 2 | 2015 | 147 | 0.560 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 600 | 0.470 |
Why?
|
| Muscle, Smooth | 1 | 2014 | 251 | 0.450 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2022 | 1335 | 0.440 |
Why?
|
| Transplantation Conditioning | 2 | 2020 | 2374 | 0.430 |
Why?
|
| Lung Diseases | 3 | 2024 | 755 | 0.350 |
Why?
|
| Aged | 18 | 2024 | 73333 | 0.340 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1690 | 0.330 |
Why?
|
| Syndrome | 2 | 2022 | 1407 | 0.320 |
Why?
|
| Adult | 22 | 2024 | 82040 | 0.310 |
Why?
|
| Thoracentesis | 3 | 2024 | 72 | 0.300 |
Why?
|
| Middle Aged | 21 | 2024 | 90352 | 0.280 |
Why?
|
| Health Care Costs | 2 | 2022 | 699 | 0.270 |
Why?
|
| Female | 28 | 2024 | 148940 | 0.270 |
Why?
|
| Male | 25 | 2024 | 128315 | 0.260 |
Why?
|
| United States | 8 | 2024 | 15861 | 0.250 |
Why?
|
| Inflammation | 3 | 2023 | 2518 | 0.250 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2353 | 0.240 |
Why?
|
| Bronchoscopy | 4 | 2019 | 481 | 0.240 |
Why?
|
| Gravitation | 1 | 2024 | 26 | 0.240 |
Why?
|
| Incidence | 4 | 2023 | 5824 | 0.230 |
Why?
|
| Bronchial Thermoplasty | 1 | 2023 | 1 | 0.230 |
Why?
|
| Spirometry | 2 | 2021 | 153 | 0.220 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2023 | 24 | 0.220 |
Why?
|
| Immune System Diseases | 1 | 2023 | 65 | 0.220 |
Why?
|
| Early Diagnosis | 1 | 2024 | 313 | 0.220 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 6177 | 0.210 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2021 | 269 | 0.210 |
Why?
|
| Pleural Effusion | 2 | 2024 | 228 | 0.210 |
Why?
|
| Cytokines | 2 | 2023 | 2825 | 0.210 |
Why?
|
| Risk Factors | 5 | 2023 | 17888 | 0.200 |
Why?
|
| Anaphylaxis | 1 | 2023 | 123 | 0.200 |
Why?
|
| Aftercare | 1 | 2023 | 252 | 0.200 |
Why?
|
| Immunologic Factors | 3 | 2021 | 672 | 0.190 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2024 | 223 | 0.190 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 172 | 0.190 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2024 | 880 | 0.190 |
Why?
|
| Machine Learning | 2 | 2023 | 360 | 0.180 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 294 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 368 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2023 | 209 | 0.180 |
Why?
|
| Azithromycin | 1 | 2020 | 79 | 0.180 |
Why?
|
| Exanthema | 1 | 2022 | 212 | 0.170 |
Why?
|
| Exudates and Transudates | 1 | 2020 | 56 | 0.170 |
Why?
|
| Antilymphocyte Serum | 1 | 2020 | 237 | 0.170 |
Why?
|
| Viruses | 1 | 2021 | 157 | 0.170 |
Why?
|
| Survival Rate | 3 | 2024 | 12541 | 0.170 |
Why?
|
| Allografts | 1 | 2022 | 686 | 0.170 |
Why?
|
| Disease Progression | 3 | 2021 | 6867 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2023 | 13414 | 0.160 |
Why?
|
| Granulation Tissue | 1 | 2019 | 26 | 0.160 |
Why?
|
| Pneumothorax | 1 | 2020 | 166 | 0.160 |
Why?
|
| Dyspnea | 1 | 2022 | 420 | 0.160 |
Why?
|
| Pleura | 1 | 2020 | 130 | 0.160 |
Why?
|
| Societies, Medical | 2 | 2024 | 1320 | 0.160 |
Why?
|
| DNA, Viral | 1 | 2021 | 756 | 0.160 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 286 | 0.160 |
Why?
|
| Unrelated Donors | 1 | 2020 | 321 | 0.160 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 77 | 0.150 |
Why?
|
| Pneumonectomy | 1 | 2024 | 862 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2023 | 698 | 0.150 |
Why?
|
| Transplantation, Homologous | 2 | 2022 | 3046 | 0.150 |
Why?
|
| Air Pollution, Indoor | 1 | 2018 | 41 | 0.150 |
Why?
|
| Environmental Monitoring | 1 | 2018 | 104 | 0.150 |
Why?
|
| Vaccination | 1 | 2024 | 1166 | 0.150 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2018 | 172 | 0.150 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2019 | 159 | 0.150 |
Why?
|
| Device Removal | 1 | 2020 | 339 | 0.150 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 2027 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2024 | 801 | 0.140 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 383 | 0.140 |
Why?
|
| Biomarkers | 3 | 2023 | 5051 | 0.140 |
Why?
|
| Trachea | 1 | 2019 | 298 | 0.140 |
Why?
|
| Medicare | 1 | 2022 | 926 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 585 | 0.130 |
Why?
|
| Rural Population | 1 | 2018 | 292 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 466 | 0.130 |
Why?
|
| Gallopamil | 1 | 2015 | 1 | 0.130 |
Why?
|
| Psychometrics | 1 | 2020 | 973 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 30998 | 0.130 |
Why?
|
| Body Weights and Measures | 1 | 2015 | 52 | 0.130 |
Why?
|
| Bronchoconstriction | 1 | 2014 | 22 | 0.120 |
Why?
|
| Calcium Channel Blockers | 1 | 2015 | 143 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 738 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 4 | 0.120 |
Why?
|
| Young Adult | 6 | 2020 | 22251 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2017 | 565 | 0.120 |
Why?
|
| Bronchial Diseases | 1 | 2014 | 46 | 0.120 |
Why?
|
| Radiology | 1 | 2019 | 426 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2014 | 48 | 0.120 |
Why?
|
| Hospitalization | 1 | 2023 | 2167 | 0.110 |
Why?
|
| Vitamins | 1 | 2014 | 149 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 602 | 0.110 |
Why?
|
| Proton Therapy | 1 | 2024 | 1637 | 0.110 |
Why?
|
| Contraindications | 1 | 2013 | 154 | 0.110 |
Why?
|
| Remission Induction | 1 | 2019 | 3656 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 120 | 0.100 |
Why?
|
| Length of Stay | 1 | 2019 | 2007 | 0.100 |
Why?
|
| Suction | 2 | 2024 | 121 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 3949 | 0.100 |
Why?
|
| Quality of Life | 4 | 2023 | 4761 | 0.100 |
Why?
|
| Recurrence | 1 | 2020 | 4878 | 0.100 |
Why?
|
| Logistic Models | 1 | 2019 | 3444 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1253 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2315 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 2057 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2014 | 617 | 0.090 |
Why?
|
| Drainage | 2 | 2024 | 462 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 5162 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 14617 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 15218 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 1330 | 0.080 |
Why?
|
| Algorithms | 1 | 2020 | 3891 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2024 | 5681 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2024 | 1260 | 0.080 |
Why?
|
| Consensus | 2 | 2023 | 1106 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2019 | 6764 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 3156 | 0.070 |
Why?
|
| Random Allocation | 2 | 2019 | 741 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4481 | 0.060 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2023 | 55 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 10708 | 0.060 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2023 | 51 | 0.060 |
Why?
|
| Excipients | 1 | 2023 | 19 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2024 | 413 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2023 | 117 | 0.050 |
Why?
|
| Chest Pain | 1 | 2024 | 173 | 0.050 |
Why?
|
| Societies | 1 | 2023 | 38 | 0.050 |
Why?
|
| Myofibroblasts | 1 | 2023 | 97 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 359 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 16689 | 0.050 |
Why?
|
| Colitis | 1 | 2024 | 341 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 197 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2023 | 1430 | 0.050 |
Why?
|
| Prognosis | 3 | 2024 | 22505 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2024 | 764 | 0.040 |
Why?
|
| Pleurodesis | 1 | 2020 | 70 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 1129 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 716 | 0.040 |
Why?
|
| Ventilation | 1 | 2018 | 19 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2024 | 1341 | 0.040 |
Why?
|
| Housing | 1 | 2018 | 67 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 7895 | 0.040 |
Why?
|
| India | 1 | 2018 | 318 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2024 | 17061 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2023 | 1654 | 0.030 |
Why?
|
| United Kingdom | 1 | 2017 | 287 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 861 | 0.030 |
Why?
|
| Stem Cells | 1 | 2023 | 1216 | 0.030 |
Why?
|
| Proteomics | 1 | 2023 | 1427 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2018 | 211 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1726 | 0.030 |
Why?
|
| Fatigue | 1 | 2022 | 1275 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2021 | 1824 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2024 | 4000 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 2197 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2023 | 1207 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 654 | 0.030 |
Why?
|
| Helium | 1 | 2014 | 23 | 0.030 |
Why?
|
| Swine | 1 | 2019 | 1607 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 5315 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 1093 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 1006 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1694 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1610 | 0.030 |
Why?
|
| Animals | 3 | 2024 | 61956 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 1939 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 300 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2014 | 117 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4492 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2017 | 33737 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2828 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 3409 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 1430 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 6509 | 0.020 |
Why?
|
| Child | 2 | 2024 | 30559 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 1608 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4328 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6449 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2580 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 9470 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 5056 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 13006 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 10400 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7381 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 35600 | 0.010 |
Why?
|